Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Meclocycline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 14/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.58 |
| ▸ | MEN1 | O00255 | 9/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.58 |
| ▸ | USP2 | O75604 | 8/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 8/20 | 0.58 |
| ▸ | RECQL | P46063 | 7/20 | 0.58 |
| ▸ | HPGD | P15428 | 7/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.58 |
| ▸ | THRB | P10828 | 6/20 | 0.58 |
| ▸ | MAPT | P10636 | 6/20 | 0.58 |
| ▸ | LMNA | P02545 | 4/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.58 |
| ▸ | CASP7 | P55210 | 2/20 | 0.58 |
| ▸ | CASP1 | P29466 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.53 |
| ▸ | MC4R | P32245 | 1/20 | 0.53 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 4/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Meclocycline SCHEMBL5505493 | 1.00 | TDP1 (0.58) | TDP1KDM4EMEN1KMT2AUSP2 | |
| Meclocycline SCHEMBL29427550 | 0.99 | TDP1 (0.59) | TDP1KDM4EMEN1KMT2AUSP2 | |
| Meclocycline SCHEMBL21133273 | 0.99 | TDP1 (0.59) | TDP1KDM4EMEN1KMT2AUSP2 | |
| Meclocycline SCHEMBL21133274 | 0.99 | TDP1 (0.59) | TDP1KDM4EMEN1KMT2AUSP2 | |
| Meclocycline SCHEMBL3445 | 0.99 | TDP1 (0.59) | TDP1KDM4EMEN1KMT2AUSP2 | |
| Meclocycline SCHEMBL24321867 | 0.99 | TDP1 (0.59) | TDP1KDM4EMEN1KMT2AUSP2 | |
| Meclocycline SCHEMBL195707 | 0.99 | TDP1 (0.59) | TDP1KDM4EMEN1KMT2AUSP2 | |
| Meclocycline SCHEMBL4207351 | 0.98 | TDP1 (0.58) | TDP1KDM4EMEN1KMT2AUSP2 | |
| Meclocycline SCHEMBL4207355 | 0.98 | TDP1 (0.58) | TDP1KDM4EMEN1KMT2AUSP2 | |
| Meclocycline SCHEMBL2072677 | 0.94 | TDP1 (0.61) | TDP1KDM4EMEN1KMT2AUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1829546-A1 | Formulations containing tetracyclines for treating or preventing mucositis | Mucosal Therapeutics LLC (US) | 2007-09-05 | — | — | EP | disclosed |
| EP-1212050-B1 | FORMULATIONS CONTAINING TETRACYCLINES FOR TREATING OR PREVENTING MUCOSITIS | MUCOSAL THERAPEUTICS LLC (US) | 2006-12-06 | — | — | EP | disclosed |
| US-20060084633-A1 | Formulations for treating or preventing mucositis | ORAPHARMA, INC. | 2006-04-20 | — | — | US | disclosed |
| US-6946118-B1 | Formulations for treating or preventing mucositis | ORAPHARMA, INC. (US) | 2005-09-20 | — | — | US | disclosed |
| US-6893665-B2 | Formulations for treating or preventing mucositis | ORAPHARMA, INC. (US) | 2005-05-17 | — | — | US | disclosed |
| US-20040029843-A1 | Rapidly disintegrating formulations for treating or preventing mucositis | ORAPHARMA, INC. | 2004-02-12 | — | — | US | disclosed |
| US-6683067-B2 | COMPRISING A POORLY ABSORBED TETRACYCLINE IN A CARRIER FOR TOPICAL ADMINISTRATION TO THE MUCOSA; REDUCES THIS SIDE EFFECT OF RADIATION OR CHEMOTHERAPY | ORAPHARMA, INC. | 2004-01-27 | — | — | US | disclosed |
| WO-2004000223-A2 | RAPIDLY DISINTEGRATING FORMULATIONS FOR TREATING OR PREVENTING MUCOSITIS | ORAPHARMA, INC. (US) | 2003-12-31 | — | — | WO | disclosed |
| EP-1212050-A2 | FORMULATIONS CONTAINING TETRACYCLINESFOR TREATING OR PREVENTING MUCOSITIS | Orapharma, Inc. (US) | 2002-06-12 | — | — | EP | disclosed |
| US-20020045604-A1 | Formulations for treating or preventing mucositis | ORAPHARMA, INC. | 2002-04-18 | — | — | US | disclosed |
| US-20020035096-A1 | Formulations for treating or preventing mucositis | VENTURE LENDING & LEASING V, INC. | 2002-03-21 | — | — | US | disclosed |
| WO-2001019362-A2 | FORMULATIONS FOR TREATING OR PREVENTING MUCOSITIS | ORAPHARMA, INC. (US) | 2001-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045604-A1 | Formulations for treating or preventing mucositis | SI, SLC10A2, TREH | TDP1 1734/4885KDM4E 4648/4885MEN1 331/4885 |
| US-20060084633-A1 | Formulations for treating or preventing mucositis | SI, TREH, SLC10A2 | TDP1 1609/4885KDM4E 4620/4885MEN1 314/4885 |
| US-20020035096-A1 | Formulations for treating or preventing mucositis | SI, SLC10A2, TREH | TDP1 1734/4885KDM4E 4648/4885MEN1 331/4885 |
| US-20040029843-A1 | Rapidly disintegrating formulations for treating or preventing mucositis | MMP17, MMP15, MMP16 | TDP1 1145/4885KDM4E 3729/4885MEN1 694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.